Concepedia

Publication | Open Access

Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers

DOIFull Paper Access

87

Citations

15

References

2007

Year

Ramesh K. Ramanathan, Merrill J. Egorin, Julie L. Eiseman, Suresh S. Ramalingam, David Friedland, Sanjiv S. Agarwala, S. Percy Ivy, Douglas M. Potter, Gurkamal Chatta, Eleanor G. Zuhowski,
Clinical Cancer Research

Abstract

The recommended phase II doses of 17AAG are 175 to 200 mg/m(2) when given twice a week and consistently cause elevations in PBMC HSP70.

References

YearCitations

Page 1